Chromosome Engineering Research Center, Tottori University, Yonago 683-8503, Japan.
BMC Biotechnol. 2010 May 6;10:37. doi: 10.1186/1472-6750-10-37.
Microcell-mediated chromosome transfer (MMCT) is a technique by which a chromosome(s) is moved from donor to recipient cells by microcell fusion. Polyethylene glycol (PEG) has conventionally been used as a fusogen, and has been very successful in various genetic studies. However, PEG is not applicable for all types of recipient cells, because of its cell type-dependent toxicity. The cytotoxicity of PEG limits the yield of microcell hybrids to low level (10-6 to 10-5 per recipient cells). To harness the full potential of MMCT, a less toxic and more efficient fusion protocol that can be easily manipulated needs to be developed.
Microcell donor CHO cells carrying a human artificial chromosome (HAC) were transfected with genes encoding hemagglutinin (H) and fusion (F) proteins of an attenuated Measles Virus (MV) Edmonston strain. Mixed culture of the CHO transfectants and MV infection-competent human fibrosarcoma cells (HT1080) formed multinucleated syncytia, suggesting the functional expression of the MV-H/F in the CHO cells. Microcells were prepared and applied to HT1080 cells, human immortalized mesenchymal stem cells (hiMSC), and primary fibroblasts. Drug-resistant cells appeared after selection in culture with Blasticidin targeted against the tagged selection marker gene on the HAC. The fusion efficiency was determined by counting the total number of stable clones obtained in each experiment. Retention of the HAC in the microcell hybrids was confirmed by FISH analyses. The three recipient cell lines displayed distinct fusion efficiencies that depended on the cell-surface expression level of CD46, which acts as a receptor for MV. In HT1080 and hiMSC, the maximum efficiency observed was 50 and 100 times greater than that using conventional PEG fusion, respectively. However, the low efficiency of PEG-induced fusion with HFL1 was not improved by the MV fusogen.
Ectopic expression of MV envelope proteins provides an efficient recipient cell-oriented MMCT protocol, facilitating extensive applications for studies of gene function and genetic corrections.
微细胞介导的染色体转移(MMCT)是一种通过微细胞融合将染色体从供体转移到受体细胞的技术。聚乙二醇(PEG)传统上被用作融合剂,在各种遗传研究中非常成功。然而,PEG 并不适用于所有类型的受体细胞,因为它具有细胞类型依赖性毒性。PEG 的细胞毒性限制了微细胞杂种的产量达到低水平(每个受体细胞 10-6 到 10-5)。为了充分发挥 MMCT 的潜力,需要开发一种毒性更低、效率更高且易于操作的融合方案。
携带人人工染色体(HAC)的微细胞供体 CHO 细胞被转染了编码麻疹病毒(MV)减毒 Edmonston 株血凝素(H)和融合(F)蛋白的基因。CHO 转染子与 MV 感染性人纤维肉瘤细胞(HT1080)的混合培养形成多核合胞体,表明 MV-H/F 在 CHO 细胞中的功能表达。制备微细胞并应用于 HT1080 细胞、人永生化间充质干细胞(hiMSC)和原代成纤维细胞。在针对 HAC 上标记选择标记基因的 Blasticidin 选择下,在培养中出现了耐药细胞。融合效率通过计数每个实验中获得的稳定克隆的总数来确定。通过荧光原位杂交(FISH)分析证实了微细胞杂种中 HAC 的保留。三种受体细胞系表现出不同的融合效率,这取决于 MV 的受体 CD46 的细胞表面表达水平。在 HT1080 和 hiMSC 中,观察到的最大效率分别比传统 PEG 融合高 50 倍和 100 倍。然而,MV 融合剂并没有改善 HFL1 中 PEG 诱导融合的低效率。
MV 包膜蛋白的异位表达提供了一种有效的面向受体细胞的 MMCT 方案,促进了基因功能和遗传纠正研究的广泛应用。